MAPT and Alzheimer disease: Depleting TBS-soluble AD brain tissue homogenates with the N-terminus-targeting antibodies tau12 and tau95–108 (epitopes: aa 6–18 and aa 95–108, respectively) as well as the mid-region antibody tau5 (aa 210–230), each led to complete removal of the tau-FRET signal (Fig. 2b,c), which taken together suggests the presence of long, near-full-length tau species.